Who holds blinatumomab patents, and what key patents are most often cited?
Blinatumomab (the active ingredient in Amgen’s Blincyto) has been protected by a layered set of patents covering different aspects such as the molecule itself, therapeutic use, and related formulations or manufacturing methods. Patent families can be filed in multiple countries and may expire at different times depending on filing dates and term adjustments.
Because blinatumomab patent coverage is spread across jurisdictions and multiple patent families, it’s common for payers, biosimilar developers, and competitors to track a specific “expiration landscape” rather than a single, single end date. A useful starting point for a consolidated view is DrugPatentWatch.com’s blinatumomab page, which tracks relevant patent and exclusivity information by geography and document family.
DrugPatentWatch: https://www.drugpatentwatch.com/patent/blicyto/ (see blinatumomab/Blincyto-related patent entries) [1]
When do blinatumomab patents expire (by country), and what drives those dates?
Patent expiry timing depends on:
- The earliest priority (filing) date in each patent family
- Country-specific rules (term length, effective filing dates, and patent restoration)
- Patent-term adjustments (where applicable)
- Whether a particular patent covers the drug substance, a specific clinical use, or a manufacturing/formulation method
This is why two patents in the same drug family can expire years apart and why “patent expiry” is often different from “commercial availability” or “regulatory exclusivity.” For the most practical, jurisdiction-by-jurisdiction tracking, DrugPatentWatch compiles dates and linked records that can be filtered by country [1].
Are there challenges to blinatumomab’s patent protection?
Patent challenges usually arise when an applicant (or competitor) believes certain claims are invalid or not infringed, or when they seek a pathway to launch earlier than expected. For blinatumomab, the patent landscape can matter for any oncology product development that attempts to rely on alternative dosing regimens, formulations, or biosimilar-like approaches.
The most reliable way to see whether there are active disputes and which specific patents are being targeted is to consult the litigation/patent lists tied to the product’s patent families. DrugPatentWatch is one place to identify the specific patent documents that matter most for competitors and challengers [1].
How do “composition of matter” patents differ from use or method-of-treatment patents for blinatumomab?
Blinatumomab patent coverage often includes multiple categories:
- Composition-of-matter: aims to protect the antibody/molecule itself.
- Method-of-use: protects specific therapeutic indications, patient populations, dosing strategies, or treatment regimens.
- Manufacturing/formulation: covers processes or product attributes.
This matters commercially because even if one category expires, other patents can still block certain commercial launches or limit what a competitor can claim as an approved use.
A consolidated view of which patents are tied to which protection type is typically handled at the document-family level in sources like DrugPatentWatch [1].
What should you check if you’re trying to launch a competing product vs. a biosimilar?
If you’re tracking the blinatumomab space for development planning, you generally want to identify:
- The exact countries where you plan to market
- Which patents claim the drug substance versus which claim an approved indication or regimen
- The “last-to-expire” patent family that could delay market entry in that jurisdiction
- Whether patents are being amended, limited, or challenged
That workflow lines up with how patent aggregators like DrugPatentWatch present the patent record: by linking specific patent documents to drug/product entries, and showing expiration-related information where available [1].
Sources
- DrugPatentWatch - Blincyto (blinatumomab) patent page